Gastrointestinal Cancers and Clinical Trials: What Patients Need to Know Earlier On

Overview

This report highlights the importance of early consultation about clinical trials for patients with gastrointestinal cancers. Breakthrough treatments are being tested, and participation in clinical trials can provide access to novel therapies that may significantly impact patient outcomes.

Background

Clinical trials are essential for advancing treatment options in gastrointestinal cancers, which are often complex and require tailored approaches. Early involvement in clinical trials can provide patients with access to cutting-edge therapies and potentially improve their prognosis. Awareness among patients and healthcare providers about the availability of these trials is crucial for optimizing treatment decisions.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

• Clinical trials offer patients access to novel therapies throughout their cancer journey.
• USC Norris Comprehensive Cancer Center has over 50 therapeutic trials for gastrointestinal malignancies.
• New immunotherapy agents and targeted therapies are expanding treatment options for esophagogastric cancers.
• Early-phase studies at USC include trials assessing new drugs and combinations for advanced cancers.
• Patients should be informed about clinical trial options before starting standard treatments.

Clinical Implications

Healthcare providers should prioritize discussions about clinical trial participation early in the treatment process for patients with gastrointestinal cancers. This approach can enhance patient access to innovative therapies and improve overall treatment outcomes.

Conclusion

Engaging patients in discussions about clinical trials from the outset is vital for maximizing treatment opportunities in gastrointestinal oncology. Early awareness and participation can lead to better patient outcomes.

Related Resources & Content

1. The ASCO Post, 2015 -- Our Patients Are the True Heroes of Cancer Research
2. The ASCO Post, 2014 -- Clinical Trials Actively Recruiting Patients With Colon or Rectal Cancer
3. The ASCO Post, 2016 -- Educating People About Clinical Trials May Improve Their Likelihood of Participation
4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), 2024
5. FDA, 2024 -- FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
6. The New Gastroenterologist — Proactively Addressing Gastrointestinal Cancers in Younger Populations
7. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
8. FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer | FDA
9. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial | Nature Medicine